Bank of New York Mellon’s Nurix Therapeutics NRIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.55M | Buy |
224,125
+19,047
| +9% | +$217K | ﹤0.01% | 2622 |
|
|
2025
Q1 | $2.44M | Buy |
205,078
+14,173
| +7% | +$168K | ﹤0.01% | 2583 |
|
|
2024
Q4 | $3.6M | Buy |
190,905
+15,639
| +9% | +$295K | ﹤0.01% | 2453 |
|
|
2024
Q3 | $3.94M | Sell |
175,266
-33,870
| -16% | -$761K | ﹤0.01% | 2409 |
|
|
2024
Q2 | $4.36M | Buy |
209,136
+49,918
| +31% | +$1.04M | ﹤0.01% | 2398 |
|
|
2024
Q1 | $2.34M | Sell |
159,218
-13,859
| -8% | -$204K | ﹤0.01% | 2686 |
|
|
2023
Q4 | $1.79M | Buy |
173,077
+2,791
| +2% | +$28.8K | ﹤0.01% | 2892 |
|
|
2023
Q3 | $1.34M | Buy |
170,286
+4,816
| +3% | +$37.9K | ﹤0.01% | 3009 |
|
|
2023
Q2 | $1.65M | Buy |
165,470
+7,161
| +5% | +$71.5K | ﹤0.01% | 2936 |
|
|
2023
Q1 | $1.41M | Sell |
158,309
-2,235
| -1% | -$19.8K | ﹤0.01% | 2988 |
|
|
2022
Q4 | $1.76M | Buy |
160,544
+1,784
| +1% | +$19.6K | ﹤0.01% | 2918 |
|
|
2022
Q3 | $2.07M | Buy |
158,760
+23,057
| +17% | +$300K | ﹤0.01% | 2829 |
|
|
2022
Q2 | $1.72M | Buy |
135,703
+31,581
| +30% | +$400K | ﹤0.01% | 2915 |
|
|
2022
Q1 | $1.46M | Buy |
104,122
+104
| +0.1% | +$1.46K | ﹤0.01% | 3097 |
|
|
2021
Q4 | $3.01M | Buy |
104,018
+5,731
| +6% | +$166K | ﹤0.01% | 2747 |
|
|
2021
Q3 | $2.95M | Buy |
98,287
+20,260
| +26% | +$607K | ﹤0.01% | 2774 |
|
|
2021
Q2 | $2.07M | Buy |
78,027
+11,329
| +17% | +$301K | ﹤0.01% | 2960 |
|
|
2021
Q1 | $2.07M | Buy |
66,698
+22,324
| +50% | +$694K | ﹤0.01% | 2901 |
|
|
2020
Q4 | $1.46M | Buy |
44,374
+16,482
| +59% | +$542K | ﹤0.01% | 3024 |
|
|
2020
Q3 | $974K | Buy |
+27,892
| New | +$974K | ﹤0.01% | 3139 |
|